IPP Bureau
Shionogi boosts stake in ViiV Healthcare in $2.125 billion deal, Pfizer exits
By IPP Bureau - January 23, 2026
Under the deal, ViiV Healthcare will issue new shares to Shionogi for $2.125 billion and cancel Pfizer’s holding
Akeso’s novel AS drug Gumokimab accepted for review by China’s drug regulator
By IPP Bureau - January 23, 2026
This marks the second indication for which gumokimab has gained NDA review acceptance
EMA hits record high in vet medicine nods for second year running
By IPP Bureau - January 23, 2026
EMA recommended 30 veterinary medicines for marketing authorisation in 2025
iRegene’s Parkinson’s therapy gains FDA designation
By IPP Bureau - January 21, 2026
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
AstraZeneca gains full global rights to AbelZeta’s CAR-T therapy in $630M deal
By IPP Bureau - January 21, 2026
Brenig Therapeutics launches first-in-human trial of novel neurodegenerative therapy
By IPP Bureau - January 21, 2026
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
Fresenius Kabi & TQ Therapeutics join forces to accelerate cell & gene therapy manufacturing
By IPP Bureau - January 21, 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
Lupin and Galenicum ink license and supply agreement for semaglutide in 23 countries
By IPP Bureau - January 21, 2026
Galenicum will oversee development, manufacturing and supply, while Lupin will handle regulatory submissions, approvals, and commercialization and distribution of Semaglutide across 23 countries globally
Novo Nordisk deepens Aspect Biosystems alliance in push for curative diabetes cell therapies
By IPP Bureau - January 21, 2026
Aspect has acquired rights to Novo Nordisk’s stem cell-derived islet cell and hypoimmune cell engineering technologies
Neurizon locks in global trademark protection across key pharma markets
By IPP Bureau - January 21, 2026
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Moderna & Merck study: mRNA therapy plus KEYTRUDA cut melanoma recurrence risk by half
By IPP Bureau - January 21, 2026
The study evaluated patients with stage III/IV melanoma after complete tumor resection
HRV Pharma & SMS LifeSciences form strategic partnership for orphan and niche APIs
By IPP Bureau - January 21, 2026
Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
By IPP Bureau - January 21, 2026
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
Medico Remedies secures government supply order of Rs. 73.23 Cr
By IPP Bureau - January 21, 2026
Medico Remedies has secured the order to supply Azithromycin 500gm (tablets) to Uttar Pradesh Medical Supplies Corporation Limited
